The BAP1-tumor predisposition syndrome (BAP1-TPDS) has been recently identified to predispose patients to a variety of cancers and preneoplastic lesions. About 130 unrelated probands have been identified worldwide; however, the impact of the syndrome is suspected to be much larger given the diversity of the cancer phenotype. To evaluate the frequency of germline BAP1 mutations in the general and cancer populations, we analyzed the Exome Aggregation Consortium (ExAC), a database that contains 53105 exomes of unrelated individuals unaffected by cancer (general population) and exomes of 7601 unrelated individuals affected by cancer provided by the Cancer Genome Atlas (TCGA, cancer subjects). BAP1 null variants were seen at much higher frequency in the cancer subjects (0.0526%) compared to the general population (0.00188%) with a relative risk of 27.93 and (P 5 0.0011, [95% CI: 3.122-249.883], Fisher's exact test). We also studied a reported BAP1 null variant, c.1203T > G, p.T401* (rs200156887), observed commonly in the general population. Sequencing and restriction fragment polymorphism of the RT-4 cell line that contains this variant revealed that it is in fact a 3bp deletion/insertion, c.1201_1203delinsGAG, a likely benign missense alteration p.Y401E explaining the relative high frequency of this variant in the general population. In conclusion, germline null mutations in BAP1 have a significantly higher frequency in cancer patients than the general population. Given the low frequency of reported families with BAP1-TPDS, our results suggest that the syndrome is underreported especially in patients with cancer. 
| R E SULTS AN D DI SC USSION
Five different BAP1 null variants, as defined by the ACMG guidelines, 9 were observed (Table  T1 1). Null variants were seen at much higher frequency in the TCGA subjects (0.0526%) compared to the general population (0.00188%) with a relative risk of 27.93 Figure  F1  1A and Table 1 ). The distribution of these missense variants in the different functional domains of BAP1 was similar in the cancer patients and general population (Figure 1 ). In addition, 3 in-frame deletions were observed in the general population but not in the cancer patients. Two of these variants, p.Gln441del and p.Glu406del, were located outside the deubeqitinase domain while 1 (p.Cys103del) was located in the deubiquitinase domain. All 3 in-frame deletions lead to a single amino acid loss. According to the established clinical guidelines, these missense and inframe deletion variants should be classified as variants of uncertain significance. 9, 12 Further laboratory functional studies will be needed for their optimal clinical classification. In addition to the 5 null variants identified (Table 1) RFLP analysis showed that the 2 variants are in cis to each other (Figure 1B) . As such, we assert that these 2 BAP1 variants are erroneously In conclusion, germline null mutations in BAP1 appear to have a significantly higher frequency in cancer patients than general population. Given the low frequency of reported families with BAP1-TPDS, our results suggest that germline pathogenic mutations in BAP1 are underreported especially in patients with cancer.
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